Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Boyeon KimYoung Soo ParkJae Sook SungJong Won LeeSaet Byeol LeeYeul Hong KimPublished in: Cancer medicine (2020)
Clathrin-mediated EGFR endocytosis contribute primary resistance of gefitinib treatment and CME inhibition combined with gefitinib could be an option in treatment of wild-type EGFR NSCLC.